Abstract: During the last decade, the application of nanotechnologies for anticancer drug delivery has been extensively explored, hoping to improve the effi cacy and to reduce side effects of chemotherapy. The present review is dedicated to a certain kind of anticancer drug nanovectors developed to target tumors with the help of an external magnetic fi eld. More particularly, this work treats anticancer drug nanoformulations based on superparamagnetic iron oxide nanoparticles coated with biocompatible polymers. The major purpose is to focus on the specifi c requirements and technological diffi culties related to controlled delivery of antitumoral agents. We attempt to state the problem and its possible perspectives by considering the three major constituents of the magnetic therapeutic vectors: iron oxide nanoparticles, polymeric coating and anticancer drug.
Introduction
Nanosciences and nanotechnologies form a growing strategic sector with enormous economic potential: "small is big business" (Maliksi 2006 ). Nanostructures and nanosystems developed include macromolecules as for example DNA, colloid particles, macromolecular assemblies, or even viruses (Emerich and Thanos 2005) . Nanosystems are governed by surface effects such as hydrophobic interactions, hydrogen bonding, ionic bonding or repulsion, covalent bonding.
There is an enormous potential for nanotechnology applied to drug delivery (Kreuter 2004; Whelan and Mayenne 2006) . The vehicle might be a functionalized nanoparticle which contains the therapeutic agent and is capable of targeting specifi c diseased cells or organs. Effi cient drug targeting is mainly explored in the fi eld of cancer treatment. As cancer cells tend to develop multidrug resistance (Baird and Kaye 2003) , and the serious side effects encountered limit the effi cacy of chemotherapy (Alexiou et al 2005) , the search for alternative treatments is currently one of the most active areas of cancer research (Sachdeva 1998) .
A number of different targeting strategies for cancer therapy have been comprehensively reviewed in many publications (Sachdeva 1998; Begent 1999) . One rational approach involves conjugating cancer chemotherapeutics with ligands specifi c to the cancer cell surface (antibodies or small molecules) in the hope of promoting their localization in tumors (Sachdeva 1998; Huang and Oliff 2001) . Another approach is magnetic drug targeting: magnetoliposomes (De Cuyper and Joniau 1988) or magnetic polymer particles (Gupta and Gupta 2005) carrying active molecules represent an attractive tool since they allow one to concentrate the drug at a defi ned target site by local application of an external magnetic fi eld. Nanoparticles of iron oxides, in particular magnetite and maghemite, have been shown to offer potential applications because of their unique magnetic properties and low toxicity (Pulfer and Gallo 2000; Lübbe et al 2001 Lübbe et al , 2003 .
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The purpose of our article is to focus on the specifi c requirements and the most recent developments related to the use of iron oxide nanoparticles for magnetically controlled delivery of anticancer drugs. The optimization of critical parameters makes the development of magnetic vectors of anticancer drugs a multidisciplinary challenge. Indeed, the success of this optimization depends not only on novel protocols of particle preparation but also on appropriate methods of physico-chemical characterization and biological evaluation in vitro and in vivo. We attempt to illustrate the state of the problem and possible perspectives by considering the three major constituents of the nanoparticular magnetic vectors: iron oxide nanoparticles, polymeric coating and anticancer drugs.
Principle, challenges and limits of magnetic drug targeting
The principle of magnetic drug targeting is relatively simple: after intravascular injection (Figure 1 ), magnetic nanoparticles can be transported by the blood circulation and concentrated at the tumor with the aid of a magnetic fi eld applied at the affected zone (Lübbe et al 2003) .
Iron oxide particles with diameters below ~30-40 nm are of particular interest because they exhibit superparamagnetic behavior (Bean and Livingstone 1959) . This means that once the magnetic fi eld is removed, they do not retain any magnetization (no hysteresis). Superparamagnetic iron oxide nanoparticles are already used as contrast media in magnetic resonance imaging, and their low toxicity has been demonstrated for a long time (Neuberger et al 2005) .
The iron oxide nanoparticles constitute the core of the fi nal forms of therapeutic nanovectors. From a physicochemical point of view, the main objective in the preparation of magnetic nanoparticles consists in a strict control of particle size and colloid stability/dispersibility under physiological conditions. These properties can be modulated by coating the particles in two different ways: either the iron oxide nanoparticles are physically incorporated in a polymer matrix, or their surface is functionalized with polymer molecules (Figure 2) . As for the drug, it can be dispersed in the polymer matrix, chemically bound to the polymer, or directly attached to the iron oxide surface. After coating, the particle size is increased, but it still should remain in the sub-micron range. In this case, they will not block vessels and capillaries and thus avoid embolization (Alexiou et al 2005) . Moreover, size and surface of resulting particles are determinant with respect to pharmacokinetics in vivo, where major limitations are quick blood clearance and non-specifi c uptake by macrophages. To maximize circulation times and targeting external magnetic field injectable suspension of nanovectors tumor target ability, the optimal size should be less than 100 nm in diameter and the surface should be hydrophilic (Bazile et al 1995; Storm et al 1995) . Ideally, these properties should render the particles "furtive", which means that they are not cleared by the reticulo-endothelial system. In addition to biocompatibility, the coating should regulate drug loading rates and release kinetics. Once at the target site, the drug is released from the magnetic carrier creating a high local concentration in the tumor tissue while minimizing the amount of the drug throughout the rest of the body (Lübbe et al 2001) . However, this implies that the magnetic fi eld must be applied long enough for the drug delivery. The magnet must create a suffi ciently strong magnetic fi eld to retain nanoparticles at the desired site. The success of the method depends on the competitive forces between the external magnetic fi eld and blood fl ow pressure in the arteries and capillaries. Another problem is the depth of the target site because the strength of the magnetic fi eld decreases with distance. This implies that one can use this technique only in the case of solid tumors close to the surface of the body (Pulfer and Gallo 2000) .
First clinical trials
Since 1996, Lübbe performed clinical trials for the treatment of breast cancer by magnetic carriers of epirubicin (Lübbe, Bergemann, Riess et al 1996) . These trials followed preclinical studies (Lübbe, Bergemann, Huhnt et al 1996) that documented tolerance and effi cacy. In the fi rst trials, epirubicin was ionically bound to a modifi ed carbohydrate layer on iron oxide nanoparticles. The authors clearly observed the accumulation of nanoparticles in the target area after exposure to the magnetic fi eld. However, the drug release was rather dependent on variable physiological parameters (Lübbe et al 2001) . Thus, technological improvements were necessary to make this treatment more effective. Nevertheless, the feasibility of the technique was demonstrated, and these results were encouraging for many researchers all over the world.
Synthesis of superparamagnetic iron oxide nanoparticles
Magnetite (Fe 3 O 4 ) is a common magnetic oxide that has a cubic inverse spinel structure (Tron et al 2000) . The most common method to prepare magnetite nanoparticles consists in mixing solutions of FeCl 3 and FeCl 2 , followed by precipitation of magnetite by addition of a base (Massart 1981) . Fe 3 O 4 nanoparticles may then be superfi cially oxidized to the more stable maghemite (γ-Fe 2 O 3 ) by addition of ferric nitrate to the colloidal suspension (Fauconnier et al 1999) . Size, shape and composition of iron oxide nanoparticles depend on the operating conditions (pH, nature of the base, Fe 2+ and Fe 3+ ratio....). The content of magnetite and maghemite in these nanoparticles can be estimated by techniques such as Mössbauer spectroscopy (Muller et al 1999) and X-ray diffraction (Lottichi et al 1998) . Recently, we have reported a possibility to deduce the magnetite/maghemite ratio in the solid phase of ferrofl uids from Raman spectra (Chourpa et al 2005) , using the ratio of their respective characteristic vibrational bands (671 cm ). It has also been observed that exposure to oxygen and elevated temperatures favored the formation in the ferrofl uids of undesirable species like antiferromagnetic hematite.
According to transmission electron microscopy (TEM) data (Figure 3a) , the iron oxide nanocrystals are nearly spherical and their size is most often described in the literature 
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to be within limits of 6-12 nm. As we mentioned above, the iron oxide nanoparticles constitute the nucleus of the fi nal nanovector which will necessarily be much bigger.
Surface properties of iron oxide nanoparticles in colloidal suspensions
The iron oxide nanoparticles can be dispersed in suitable solvents to form homogenous suspensions called ferrofl uids or magnetic fl uids. They present a very interesting amphoteric character ( Figure 4 ) due to the presence of hydroxyl groups at their surface (Fauconnier et al 1999) . Because the stability of an aqueous ferrofl uid is mainly due to electrostatic repulsion between charged particles, they fl occulate around the point of zero charge (PZC, established around pH 7). Typically, the iron oxide nanoparticles are used as cationic ferrofl uids, which means that the particle surface is positively charged and accompanied by anionic counterions (usually nitrates).
A PZC close to physiological pH should not necessarily be considered an inconvenient, as the particles still have to be coated before injection. Thus, the iron oxide nanoparticle is just a precursor, and its surface properties need only be compatible with coating and drug loading. As the nanoparticles have large surface area/volume ratios, they tend to adsorb plasma proteins and agglomerate in vivo. As a result, without coating the ferrite nanoparticles are rapidly cleared by macrophages in the reticulo-endothelial system.
As we noted above, one possibility of coating is to encapsulate the magnetic particles in a solid polymer matrix (Figures 2a and 3b) . Alternatively, the hydroxyl groups at the surface of iron oxide nanoparticles can be used to directly anchor active molecules or polymers. To enrich the choice of possible reactions, one can use silanes (Figure 4 insert) as coupling intermediates : silanes form Fe-O-Si bonds with the particle surface and offer on their opposite end functional groups (amines, thiols) that can interact with therapeutical agents, biologically relevant ligands and polymers (Xu et al 1999) .
Association of iron oxide nanoparticles with pharmaceutical polymers by encapsulation
In this case, the objective is to formulate multi-functional nanoparticular carrier systems with magnetic material in a solid polymer matrix (Häfeli 2004 ). An important challenge in the preparation of magnetic polymer particles, especially for drug targeting application, is that the magnetite content of the polymer particles should be large enough to permit magnetic guidance and delivery of these magnetic particles to the target site. Actually, it seems diffi cult to conclude about the minimum magnetic content required.
Among a wide variety of synthetic biodegradable polymers, only a few are biocompatible and commonly used to manufacture polymeric nanoparticles for medical applications. They include poly(alkylcyanoacrylates), 
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Magnetic nanoparticular vectors of anticancer drugs poly(methylidene malonate), polyanhydrides, polyorthoesters and polyesters such as poly(lactic acid), poly(glycolic acid), poly(ε-caprolactone) and their copolymers (Barratt 2000) .
Defi ned spherical magnetic microspheres were made for the fi rst time at the end of the 1970s by Widder et al (1979) . They engineered magnetic albumin microspheres containing doxorubicin at low doses and demonstrated their utilitity in an animal tumor model (Widder et al 1980 (Widder et al , 1983 . However, these albumin particles were generally not smaller than 1 μm which precludes intravenous administration. In addition, albumin has the disadvantage of possibly provoking an immune response, so interest has been progressively focused on magnetite particles covered with dextranes and/or synthetic polymers. Ibrahim described for the fi rst time the preparation of polyalkylcyanoacrylate nanoparticles loaded with magnetite and an anticancer drug, dactinomycin (Ibrahim et al 1982) . Magnetic polyalkylcyanoacrylate nanoparticles were prepared by anionic polymerization of the monomer (isobutylcyanoacrylate) in the presence of magnetite nanoparticles of between 10 and 50 nm. Final vectors included co-encapsulated dactinomycin drug and had a diameter smaller than 0.3 μm. These nanovectors responded to a magnetic fi eld after intravenous administration in mice. A few years later, Hung prepared polymer-coated submicron magnetic nanoparticles carrying the anticancer agent methotrexate (Hung et al 1990) by in situ polymerization of polyglutaraldehyde. Methotrexate is used in the treatment of various solid tumors. Their results demonstrated that the magnetic nanoparticles contained about 8% (w/w) of Fe 3 O 4 and the drug loading rates varied between 40 to 94 μg per mg of nanoparticles. In conclusion, the authors suppose that these magnetic nanoparticles may offer active drug targeting for cancer chemotherapy, but it should be necessary to increase the entrapment of magnetite to allow effi cient retention of the carrier at the target site.
More recently, Arias reported a method to prepare colloidal composite particles consisting of a magnetite core and a biodegradable polymeric shell of poly(ethyl-2-cyanoacrylate) by anionic polymerization (Arias et al 2001) . Despite the fact that the polyalkylcyanoacrylate family is considered of high interest as polymeric substrate in the realization of injectable nanoparticulate delivery systems (because of their mechanical properties, biodegradability and biocompatibility), their biodegradation products may be more toxic than those of other biodegradable/biocompatible polymers. In 1999, Zaitsev synthesized stable polymer coated magnetite nanoparticles by seed precipitation polymerization of methacrylic acid and hydroxyethyl methacrylate in the presence of nanophase magnetite (Zaitsev et al 1999) . Deng described the preparation of magnetic polymeric particles via inverse microemulsion polymerization using acrylamide as water-soluble monomer (Deng et al 2003) . They obtained water-dispersible magnetic polymeric nanoparticles with a size ranging from 80 to 180 nm. According to the authors, the magnetite concentrations in polymer particles were between 5% and 23% (w/w). However, the way in which magnetite content was determined from the values of saturation magnetization is not detailed.
Another polymer useful for encapsulation of magnetite particles is biodegradable poly(D,L-lactide) (PLA). This completely amorphous polymer is widely used in medical and pharmaceutical applications due to its very low toxicity and immunological response (Visscher et al 1985) .
Müller described coating magnetite nanoparticles with polylactide and polylactide/glycolide (PLA and PLAGA) by introducing under stirring an ethanolic magnetite dispersion into the melted polymers (Müller et al 1996) . After solidifi cation, the mass was ground to reduce the particle size to 570 nm. The relatively low cytotoxicity of these magnetiteloaded PLA and PLAGA nanoparticles was demonstrated in vitro on human granulocytes.
Gomez-Lopera prepared PLA-magnetite composite nanoparticles using big magnetite crystals with a size of about 160 nm (Gomez-Lopera et al 2001). The average diameter of coated particles was 180 nm. It seems possible that in this case the coverage of magnetite by PLA was very thin and incomplete. Thereafter, much interest has been focused on the use of composite nanoparticles prepared with poly(D,L-lactide-co-glycolide) (PLGA) polymer. The degradation of this FDA-approved polymer could be controlled by molecular weight, crystallinity and the ratio of lactide to glycolide.
One of the technical limitations with hydrophobic polymers like PLA or PLGA is the diffi culty to entrap high concentrations of hydrophilic ferrofl uids. To circumvent this problem, our group has modifi ed the surface of magnetite nanoparticles by adsorption of oleic acid before encapsulation in PLGA by a modifi ed solvent emulsifi cation/evaporation technique . This allowed the magnetite encapsulation effi ciency to be increased up to 60%. Nevertheless, the magnetite loading was rather low -about 1% (w/w) -and should be increased. The composite nanoparticles were found to have a mean diameter within the range of 270-370 nm.
At the same time, Lee prepared magnetic poly(D,Llactide-co-glycolide) nanoparticles by an emulsifi cationdiffusion method (Lee et al 2005) . Iron oxide nanoparticles (8-20 nm) were embedded in the PLGA matrix and the resulting iron oxide nanoparticles encapsulated have a size varying from 90 to 180 nm. Magnetic susceptibility of these nanoformulations increased as their size decreased. This was apparently related to the volume fraction of magnetic nanoparticles which increases when the size of the fi nal particles decreases. Unfortunately, no indication was given on the iron oxide content.
Asmatulu reported model studies on magnetic control of magnetite nanoparticles embedded in poly(L-lactide), poly(D,L-lactide) and poly(ε−caprolactone) (Asmatulu et al 2005) . The magnetic retention of composite nanoparticles in a fl exible tube was measured as a function of various parameters such as magnetic saturation, magnet distance, fl uid speed, particle size and solid content. All these parameters were proven to infl uence the capture of the magnetic particles by an external magnetic fi eld but, unfortunately, no indication was given on the range of values needed to attain this objective in vivo.
Although biocompatible, PLA or PLGA coating is not furtive because of its hydrophobic surface. Therefore, to obtain furtive nanovectors, the PLGA particles need an additional surface treatment with hydrophilic polymers. This remark leads one to the necessity to develop protocols of chemical bonding of hydrophilic polymers to the nanoparticle surface. In fact, such bonding can also be applied directly to iron oxide nanoparticles.
Treatment of the iron oxide surface for enhanced furtivity and reduced agglomeration PEG-modifi ed iron oxide nanoparticles
To increase both the stability and furtivity of magnetic suspensions, iron oxide nanoparticles are often coated with hydrophilic polymers adsorbed or chemically attached to their surface. Polyethylene glycol (PEG) seems to be one of the most appropriate ones because of its unique properties such as hydrophilicity, fl exibility, nontoxicity, and non immunogenicity.
Data from physico-chemical characterization indicate that coating with PEG efficiently reduces nanoparticle agglomeration (Gupta and Gupta 2005) . A fi rst study to show that polyethylene oxide exhibits low protein adsorption was performed by Jeon and Andrade (Jeon and Andrade 1991) .
Consecutively to this study, many authors tried to link such polymers to the surface of different kinds of nanoparticles with the hope to decrease their uptake by the mononuclear phagocyte system (Storm et al 1995) . Zhang et al (2002) immobilized silane-modifi ed PEG on the surface of magnetite nanoparticles. A rather similar approach for coating PEG to magnetic nanoparticles was proposed by Butterworth et al (2001) .
Using fl uorimetry, confocal fl uorescence microscopy and inductively coupled plasma emission spectroscopy (ICP), Zhang et al (2002) measured the uptake of their magnetic nanoformulations in breast cancer cells (BT20cells) and in mouse macrophage cells (RAW 264.7). The results of this study suggest that PEG coating of iron oxide nanoparticles limits protein adsorption on their surface and avoids their recognition by macrophages. Furthermore, PEG-modifi ed surfaces facilitate incorporation of nanoparticles by cancer cells, probably due to a high affi nity of the polymer to cellular membranes.
The main diffi culty with using PEG for the formulation of nanovectors is that, except for the terminal (hydroxyl) group, this long-chain polymer lacks functional groups useful to attach therapeutic agents and/or specifi c ligands. Zhang circumvented this diffi culty by introducing PEG modifi ed with a trifl uoroethylester-silane terminus (Kohler et al 2004) . This modifi cation allowed them to bind a folic acid ligand to PEG-treated magnetic nanoparticles. Since folate receptors are overexpressed on membranes of many cancer cells, the folic acid ligand should provide better access of nanovectors to tumors. In this way, the targeting effi cacy should be additionally increased because the therapeutic vectors will be retained by both the recognition of a ligand and the magnetic fi eld. As interesting as this strategy is, it seems to be less appropriate for grafting an anticancer agent, because it will provide limited drug loading rates.
Gupta also studied iron oxide nanoparticles modifi ed with PEG and found them to be internalized within lysosomes of fi broblasts (Gupta and Curtis 2004) . In a different way, Acar covered iron oxide nanoparticles with PEGylated polymers (Acar et al 2005) . In that case, the coating consisted of two layers, the inner layer consisting of an ionic surfactant such as 10-undecenoic acid, and the outer layer made of PEG modifi ed by esterifi cation with the same surfactant. These particles were synthesized according to various modes of preparation and present really interesting sizes for a possible administration in vivo. Furthermore, this way of synthesis offers interesting perspectives for fi xation of various watersoluble polymers.
Polysaccharide-modifi ed iron oxide nanoparticles
As an alternative to PEG, natural polymers such as dextran, chitosan or starch can be attached to the surface of iron oxide nanoparticles in order to minimize the adsorption of proteins and to protect them from macrophages (Gupta and Gupta 2005) . Dextran is a polymer of anhydroglucose having mainly alpha-D(1-6) linkages with side chains attached to the 3-positions of the backbone glucose units. A little more than twenty years ago, Molday and Mackenzie prepared iron oxide nanoparticles modifi ed with dextran (Molday and Mackenzie 1982) . They mixed a solution of ferrous chloride and ferric chloride with dextran under alkaline conditions. Similar preparations, where dextran was physically adsorbed, were then studied by various authors (Pardoe et al 2001; Bautista et al 2005) . Recently, Xu et al (2005) contributed to optimize the protocol by their study of various operating conditions. The authors reported that reaction time and size of the polymer are the main parameters essential for the quality of preparations. The high biological tolerance (Lacava et al 2004) of these modifi ed particles has been demonstrated and justifi ed their extensive use as contrast agents for magnetic-resonance imaging (MRI).
Incorporation of anticancer therapeutic agents in magnetic nanoformulations
The challenges described in this section are among the more diffi cult and important to resolve. The association of drugs with nanovectors implies three main requirements. Firstly, the drug loading should be realistic to generate effi cient therapeutic concentrations. Secondly, the drug-nanovector association should be reversible and have no consequences on biological activity of the therapeutical agent. Finally, the drug release profi les should be compatible with a reasonable duration of the treatment.
Encapsulation of the drug
The association could be realized by physical encapsulation of both drug and magnetic particles in a polymer matrix. In this case, the release of the drug will depend on the degradation or swelling of the polymer in the body. Although this approach is widely used to include active molecules in polymers (Puisieux et al 1994) , only a few groups have combined these polymers simultaneously with drugs and magnetic materials (Ibrahim et al 1982; Hung et al 1990) .
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Alternatively, the drug can be incorporated into magnetic nanoformulations through chemical bonds with the iron oxide surface or the polymer coating. Many authors described the conjugation of anticancerous agents with a polymer in the absence of iron oxides. The idea was to use macromolecules as carriers for anticancer drugs mainly to improve their biodistribution and resistance to degradation and thus prolong their activity (reviewed in Kopecek et al 2000) . As above, this type of drug charged polymer could one day be applied to the concept of magnetic drug targeting.
Ionic binding of the drug to magnetic nanoparticles
As an example where the drug is attached to the polymer by ionic attraction, one can cite nanoparticles loaded with epirubicin anticancer drug via interaction of its amino sugar with the anionic group of a modifi ed polymer (Bergemann et al 1999) . This nanoformulation was used in the clinical trials described above (Lübbe, Bergemann, Riess et al 1996) . Following the success of the fi rst clinical trials, the authors continued to study conditions of the drug release, distribution and mechanism of action both in vivo and in vitro. On the basis of commercial iron oxide nanoparticles, the same group developed a novel nanoformulation covered with modifi ed starch to which the therapeutic agent mitoxantrone was ionically bound . Mitoxantrone is used in the treatment of a wide spectrum of tumors. To this end, the polymer must be initially functionalized by introducing for example anionic phosphate groups. An enormous advantage of this protocol is that it allows one to bind to the nanoparticles very different organic molecules, as long as they possess positively charged groups. Under physiologically relevant conditions in vitro, mitoxantrone was released from the magnetic nanoparticles in less than one hour. Biodistribution and activity in vivo of this nanoformulation was assessed via the detection of mitoxantrone and of the nanoparticles (labeled with 59 Fe and 123 I) in tumors and in neighboring zones and organs . Suspensions of nanovectors were injected intra-arterially for treatment of VX2 squamous cell carcinoma in rabbits, with only 50% of the usual systemic dose (Alexiou et al 2005) . A magnetic fi eld was applied over the tumor for a duration of one hour. In comparison to control experiments without magnetic retention, the drug concentrations obtained in tumors under magnetic fi eld were largely higher and could explain remissions observed in spite of the lower amount of drug administered.
Covalent binding of the drug to magnetic nanoparticles
As described above, the main inconvenient of ionic binding is that the drug release depends on physiological parameters. To prevent this, another strategy is to couple the drug via a covalent bond to the iron oxide surface or to the polymer coating. The more current coupling agent for covalent binding directly to the iron oxide surface is aminopropylsilane (Kobayashi and Matsunaga 1991; Xu et al 1997 Xu et al , 1999 Zhang et al 2002) . Aminopropylsilane presents the advantage to possess a reactive primary amino group that reacts for example as well with an aldehyde group to form a Schiff base as with a carboxylic acid group to form a peptide bond. For many years, proteins have been extensively immobilized on inorganic supports such as magnetite via silane coupling agents (Weetall 1993) . This methodology has then been applied to grafting drugs and/or polymers on iron oxide nanoparticles, one of the best examples being the study of Zhang (2002) described above.
Recently, Kohler bound methotrexate via this method (Kohler et al 2005) . Methotrexate has structural similarity with folic acid. This similarity could be favorable to the internalization of methotrexate by cancer cells. Magnetic nanoforms of methotrexate reduced the viability of human cervical cancer cells (Hela cell line), as well as that of human breast cancer cells (MCF-7 cell line) in culture. Cellular uptake of the nanovectors in these cells was observed by TEM and quantifi ed through measurement of iron concentrations by ICP. The data indicated that the vectors were accumulated into the lysosomes, where proteases should be able to cleave the amide bond between the drug and the magnetic particle. In fact, release of methotrexate in the presence of proteases was demonstrated in vitro (Kohler et al 2005) . Internalization of the nanovectors and lysosomal release of the drug were presented as promising parameters for anticancer activity.
The necessity of internalization of the whole vector particles will depend on the general strategy adopted for the drug delivery. If the drug is covalently bound and needs specifi c enzymes or lower pH in lysosomes to trigger drug release, the whole particles have to enter the cell. Otherwise, simple diffusion through the polymer may be suffi cient to desorb the drug from the particle. Thus, cellular uptake of magnetic nanovectors is not a necessary condition for their anticancer activity. Indeed, nanovectors could stimulate drug uptake by cancer cells by locally providing high extracellular concentrations of the drug and/or by direct action on the permeability of cellular membranes (Hong et al 2006) . From this point of view, drug release from nanovectors in close vicinity of Magnetic nanoparticular vectors of anticancer drugs cancer cells could be suffi cient to bring a real advance in effi cacy of cancer chemotherapy.
Final remarks
Magnetic drug targeting is a novel drug delivery system that has been proven feasible resulting in an increase in local drug concentration and thus permitting a reduction of side effects. Nevertheless, the clinical trials highlight numerous problems still to be resolved. If the principle of magnetic drug targeting is simple, the development of magnetic vectors is complex. The critical parameters to optimize are size, magnetization, biocompatibility, and drug loading and release. Although for the time being no preparation satisfi es all requirements simultaneously, most research groups succeed to produce biocompatible magnetic vectors with controllable sizes in the nanometer range. This is a source of optimism for a real possibility of magnetically targeted chemotherapy.
